Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Prager, GW; Oehler, L; Gerger, A; Mlineritsch, B; Andel, J; Petzer, A; Wilthoner, K; Sliwa, T; Pichler, P; Winder, T; Heibl, S; Gruenberger, B; Laengle, F; Hubmann, E; Korger, M; Pecherstorfer, M; Djanani, A; Neumann, HJ; Philipp-Abbrederis, K; Wöll, E; Trondl, R; Arnold-Schrauf, C; Eisterer, W.
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Eur J Cancer. 2021; 143:101-112
Doi: 10.1016/j.ejca.2020.11.003
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Gerger Armin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients with metastatic PC (mPC). However, the clinical evidence of nab-P/G in the elderly (>70 years), who account for the majority of patients with mPC, is limited. This is the first prospective, multicentre, non-interventional study evaluating the tolerability and effectiveness of nab-P/G in younger (≤70 years) versus elderly (>70 years) patients with mPC in the daily clinical routine. METHODS: Eligible patients with mPC were treated with nab-P/G and observed until disease progression or unacceptable toxicity. The primary objectives were safety and tolerability of nab-P/G, and the secondary objectives were efficacy and real-life dosing. RESULTS: A total of 317 patients with mPC (median age, 70 years) were recruited, of which 299, aged ≤70 (n = 162) and >70 (n = 137) years, were eligible for analysis. Baseline characteristics and the safety profile were comparable between the groups. However, fatigue (22.8% versus 13.0%) and decreased appetite (8.8% versus 1.2%) were more frequent in elderly patients. Younger versus elderly patients equally benefited in terms of objective response rate (36% versus 48%), median progression-free survival (5.6 versus 5.5 months; hazard ratio [HR] = 1.03; p = 0.81) and OS (10.6 versus 10.2 months; HR = 0.89; p = 0.4). In addition, the median treatment duration (5 versus 4 cycles), relative dose intensity (70% versus 74%) or reasons for treatment discontinuation were similar. Most patients (56.2% versus 47.4%) benefited from a second-line therapy. CONCLUSION: This prospective real-world analysis confirms the feasibility and tolerability of nab-P/G treatment and reveals OS data similar for younger patients and elderly patients aged >70 years. CLINICALTRIALS. GOV REGISTRATION: NCT02555813. AUSTRIAN NIS REGISTRY: NIS005071.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Albumins - pharmacology, therapeutic use
- Antineoplastic Combined Chemotherapy Protocols - pharmacology, therapeutic use
- Deoxycytidine - analogs & derivatives, pharmacology, therapeutic use
- Female - administration & dosage
- Humans - administration & dosage
- Male - administration & dosage
- Paclitaxel - pharmacology, therapeutic use
- Pancreatic Neoplasms - drug therapy, pathology
- Find related publications in this database (Keywords)
- Gemcitabine
- Prospective study
- Survival rate
- Albumin-bound paclitaxel
- Pancreatic cancer
- Duration of therapy
- Progression-free survival
- Austria (MeSH)